Product Code: ETC7663991 | Publication Date: Sep 2024 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Israel Transthyretin Amyloidosis Treatment Market is witnessing growth due to increasing awareness among healthcare professionals and patients about this rare genetic disease. The market is driven by the rising prevalence of Transthyretin Amyloidosis, advancements in diagnostic techniques, and the introduction of novel treatment options such as gene-silencing therapies. Key players in the market are investing in research and development activities to introduce innovative therapies that can effectively manage the symptoms and slow down disease progression. Additionally, collaborations between pharmaceutical companies and research institutions are further fueling market growth. Despite these positive trends, challenges such as high treatment costs and limited access to specialized healthcare services remain, underscoring the need for continued efforts to improve patient outcomes in the Israel Transthyretin Amyloidosis Treatment Market.
The Israel Transthyretin Amyloidosis Treatment Market is witnessing a surge in research and development efforts focused on innovative therapies and precision medicine approaches. With the increasing prevalence of transthyretin amyloidosis in Israel, there is a growing demand for effective treatment options that can improve patient outcomes and quality of life. Opportunities in the market include collaborations between pharmaceutical companies and research institutions to develop novel therapies, as well as the introduction of gene-silencing technologies such as RNA interference for targeted treatment. Additionally, advancements in early diagnosis techniques and personalized medicine are poised to revolutionize the management of transthyretin amyloidosis in Israel, offering new avenues for therapeutic intervention and improved patient care.
In the Israel Transthyretin Amyloidosis Treatment Market, several challenges are faced, including limited awareness among healthcare professionals and patients about the disease, resulting in delayed diagnosis and treatment initiation. Additionally, the high cost of available treatments and limited reimbursement options pose a significant barrier to access for many patients. The market also faces challenges related to the availability of specialized healthcare centers and trained medical professionals with expertise in managing this rare disease. Furthermore, the need for ongoing research and development efforts to improve treatment options and outcomes presents a continuous challenge in the Israel Transthyretin Amyloidosis Treatment Market.
The Israel Transthyretin Amyloidosis Treatment Market is primarily driven by factors such as increasing prevalence of transthyretin amyloidosis (ATTR) in the country, growing awareness among healthcare professionals and patients, advancements in diagnostic techniques, and the availability of novel treatment options. Additionally, the rising geriatric population, improving healthcare infrastructure, and increasing research and development activities in the field of amyloidosis contribute to the market growth. Furthermore, collaborations between pharmaceutical companies and research institutions for developing innovative therapies, along with favorable government initiatives and reimbursement policies, are expected to propel the market further. Overall, the market is poised for growth due to these driving factors, creating opportunities for market players to expand their presence and offerings in Israel.
The Israel government has implemented various policies to support the treatment market for Transthyretin Amyloidosis (ATTR). These policies include providing reimbursement for approved ATTR treatments through the country`s healthcare system, ensuring that patients have access to necessary medications. Additionally, the government has set guidelines for the approval and regulation of new ATTR treatments, ensuring safety and efficacy standards are met. The government also supports research and development in the field of ATTR treatment through funding and partnerships with academic institutions and pharmaceutical companies. Overall, these policies aim to improve access to effective treatments for ATTR patients in Israel and promote innovation in the field.
The future outlook for the Israel Transthyretin Amyloidosis Treatment Market appears promising, with a growing awareness of the disease leading to increased diagnosis rates and a rising demand for effective treatment options. The market is expected to witness significant growth due to advancements in medical research, innovative therapies, and improved access to healthcare services. Additionally, collaborations between pharmaceutical companies and research institutions are likely to drive the development of novel treatment approaches for Transthyretin Amyloidosis in Israel. With an aging population and a higher prevalence of amyloid-related disorders, the market is poised for expansion, presenting opportunities for market players to introduce new therapies and cater to the unmet medical needs of patients with Transthyretin Amyloidosis in the country.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Transthyretin Amyloidosis Treatment Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Transthyretin Amyloidosis Treatment Market - Industry Life Cycle |
3.4 Israel Transthyretin Amyloidosis Treatment Market - Porter's Five Forces |
3.5 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Therapy, 2021 & 2031F |
3.7 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.8 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Transthyretin Amyloidosis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Israel Transthyretin Amyloidosis Treatment Market Trends |
6 Israel Transthyretin Amyloidosis Treatment Market, By Types |
6.1 Israel Transthyretin Amyloidosis Treatment Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By ATTR-PN, 2021- 2031F |
6.1.4 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By ATTR-CM, 2021- 2031F |
6.2 Israel Transthyretin Amyloidosis Treatment Market, By Therapy |
6.2.1 Overview and Analysis |
6.2.2 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.2.3 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By OnpattroInotersen, 2021- 2031F |
6.2.4 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Vyndaqel/Vyndamax, 2021- 2031F |
6.2.5 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Supportive Therapy, 2021- 2031F |
6.2.6 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Pipeline Therapy, 2021- 2031F |
6.3 Israel Transthyretin Amyloidosis Treatment Market, By Disease Type |
6.3.1 Overview and Analysis |
6.3.2 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Hereditary Transthyretin Amyloidosis, 2021- 2031F |
6.3.3 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Polyneuropathy, 2021- 2031F |
6.3.4 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Cardiomyopathy, 2021- 2031F |
6.3.5 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Mixed Type, 2021- 2031F |
6.3.6 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Wild Type Amyloidosis, 2021- 2031F |
6.4 Israel Transthyretin Amyloidosis Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Specialty Pharmacies, 2021- 2031F |
6.4.4 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.5 Israel Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Israel Transthyretin Amyloidosis Treatment Market Import-Export Trade Statistics |
7.1 Israel Transthyretin Amyloidosis Treatment Market Export to Major Countries |
7.2 Israel Transthyretin Amyloidosis Treatment Market Imports from Major Countries |
8 Israel Transthyretin Amyloidosis Treatment Market Key Performance Indicators |
9 Israel Transthyretin Amyloidosis Treatment Market - Opportunity Assessment |
9.1 Israel Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Therapy, 2021 & 2031F |
9.3 Israel Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.4 Israel Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Transthyretin Amyloidosis Treatment Market - Competitive Landscape |
10.1 Israel Transthyretin Amyloidosis Treatment Market Revenue Share, By Companies, 2024 |
10.2 Israel Transthyretin Amyloidosis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |